FEMY (Femasys) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


FEMY Femasys Inc FEMY
56 GF Score
Price $4.02
GF Value $12.12
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys NonCurrent Deferred Liabilities?

Femasys FEMY +1.53% 56 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates FEMY with a GF Score™ of 56/100 and a GF Value™ of $12.12 (Possible Value Trap). The stock has 7 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Femasys's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Femasys NonCurrent Deferred Liabilities Related Terms

Femasys NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Femasys's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Femasys NonCurrent Deferred Liabilities Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Femasys Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FEMY
56GF Score
Femasys Inc FEMY
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Femasys (FEMY) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Femasys and its competitors.
Is Femasys' NonCurrent Deferred Liabilities too high?
Femasys' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Femasys has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' NonCurrent Deferred Liabilities compare to UEEC and BNGO?
Femasys' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Devices & Instruments company?
A good NonCurrent Deferred Liabilities depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Femasys and its competitors. Femasys's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.12, compared to a current price of $4.02 — trading 66.8% below its estimated fair value. The current NonCurrent Deferred Liabilities is $0.00 Mil. Femasys' overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Femasys (FEMY), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $4.02 is trading 66.8% below its estimated GF Value™ of $12.12. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • NonCurrent Deferred Liabilities: $0.00 Mil
  • GF Value™: $12.12 vs. price of $4.02 (66.8% below fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
56GF Score

Get the complete analysis for FEMY

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.02
Price
$12.12
GF Value